DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the CHUM

January 21 16:13 2019 Print This Article

BROSSARD, Quebec, Jan. 22, 2019 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS” or the “Company”) (TSX Venture Exchange: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today, further to our initial news release dated June 5th, 2018, the extension through May 2019 of the technological showcase for the automated detection of Diabetic Retinopathy at the Centre Hospitalier de l’Université de Montréal (CHUM).

Technological showcase
DIAGNOS will continue screening for diabetic retinopathy at the CHUM until the end of May 2019. Because of excellent initial screening results, the administration of the CHUM has elected to extend the duration of the technological showcase to further appreciate the benefits.

AI for detection and triage
Our early detection service includes an automated AI analysis of fundus imagery together with a triage system according to the degree of severity. This proprietary service is only available via our CARA telehealth platform (Computer Assisted Retina Analysis).

Improving patient services
The DIAGNOS automated screening solution significantly increases accessibility for diabetic and hypertensive patients subject to annual screening. Screening is done at the service centre using fundus photography. The process is fast, painless, and very simple for the patient. The CARA platform will facilitate identification and expedited triage of patients suffering from retinopathies who have been referred to the ophthalmology department following a consultation at the endocrinology or diabetes clinic.

DIAGNOS is also announcing the resignation of Mr. Jean-Yves Thérien from his position as director and chairman of the audit committee of the Corporation due to personal reasons. “On behalf of my fellow board members, I would like to sincerely thank Jean-Yves for his dedication and important contribution to the development of DIAGNOS”, said Mr. Georges Hébert, Chairman of the Board of directors. The Corporation is in the process of finding Mr. Thérien’s replacement as chairman of the audit committee. In the interim, Mr. Hébert will assume the role of chairman of the audit committee.

DIAGNOS has screened to date more than 250,000 diabetic patients. Thanks to the support of the Government of Quebec and our collaboration with the CHUM, this technological showcase will allow Diagnos to demonstrate our expertise in the province. We strongly believe this partnership will also help set up extensive screening campaigns in other Canadian provinces and in the United States.

About CARA
CARA is a proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.

Additional information is available at www.diagnos.com  and www.sedar.com

For further information, please contact:

Mr. André Larente, President
Tel: 450-678-8882 ext. 224
[email protected]
Josh Falle
Momentum PR
Tel: 514-416-4656
[email protected]

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

view more articles

About Article Author

Jessica Simpson
Jessica Simpson

Jessica is the founder and editor-in-chief of TrustedNerd.com. Covering major tech shows such as CES, Jessica is always there for the latest tech news. Want your gadget to be reviewed or have a release you'd like to be considered for publishing? Send Jessica an email, jessica [at] trustednerd.com

View More Articles


  1. … [Trackback]

    […] Find More on to that Topic: trustednerd.com/2019/01/21/diagnos-announces-an-extension-to-the-diabetic-retinopathy-screening-services-assisted-by-artificial-intelligence-ai-at-the-chum/ […]